# A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

> **NCT04830137** · PHASE1 · RECRUITING · sponsor: **Nurix Therapeutics, Inc.** · enrollment: 248 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Waldenstrom Macroglobulinemia (WM)
- Mantle Cell Lymphoma (MCL)
- Marginal Zone Lymphoma (MZL)
- Follicular Lymphoma (FL)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Primary Central Nervous System Lymphoma (PCNSL)

## Interventions

- **DRUG:** NX-2127

## Key facts

- **NCT ID:** NCT04830137
- **Lead sponsor:** Nurix Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-05
- **Primary completion:** 2026-05
- **Final completion:** 2027-05
- **Target enrollment:** 248 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830137, "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04830137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*